Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 6Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Stomach Neoplasms 1Pharyngeal Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Melanoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Gestational Trophoblastic Disease 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

pembrolizumab 13Nivolumab 6Docetaxel 6cemiplimab 5avelumab 5atezolizumab 5Trastuzumab 5Carboplatin 4durvalumab 3Polymerase Chain Reaction 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Gemcitabine 3Fluorouracil 3Cisplatin 3Biopsy 3zimberelimab 2utomilumab 2ulixertinib 2tisotumab vedotin 2pertuzumab 2palbociclib 2belinostat 2amminedichloro(2-methylpyridine)platinum(II) 2Tetrahydrouridine 2Radiotherapy 2Radiosurgery 2Oxaliplatin 2Nicotine 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × zimberelimab × Head & Neck × Clear all
NCT05891171 2026-06-05

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
48 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡